Status:
COMPLETED
The Use of Low Molecular Weight Heparin in Traumatic Brain Injury
Lead Sponsor:
Hennepin Healthcare Research Institute
Collaborating Sponsors:
Aventis Pharmaceuticals
Conditions:
Brain Injury
Venous Thrombosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To study the safety and efficacy of early administration of Low Molecular Weight Heparin to patients with traumatic brain injury.
Detailed Description
Venous thromboembolic (VTE) prophylaxis in trauma patients is a critical clinical problem. Patients with traumatic brain injury usually have effective VTE prophylaxis withheld secondary to concerns of...
Eligibility Criteria
Inclusion
- Blunt traumatic brain injury (Marshall II-V)
- Stable 6 hr. head CT
- Stable hemoglobin
Exclusion
- Premorbid coagulopathy
- Pregnancy
- \< 18 y.o.
- Need for therapeutic anticoagulation
- Heparin allergy
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00170378
Start Date
December 1 2002
End Date
August 1 2005
Last Update
June 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415